Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Alfa Wassermann Proteomic Technologies (AWPT) was a specialized division of Alfa Wassermann focused on the development of automated systems for protein separation and fractionation. The company's core technology centered on continuous flow ultracentrifugation, embodied in its flagship AW Promatix system, which was designed to streamline biomarker discovery and proteomic research. By providing high-resolution separation of complex biological samples, AWPT aimed to improve the efficiency of downstream analysis in drug discovery and diagnostics. Following the 2015 merger of its parent company with Sigma-Tau, the business operations were integrated into the Alfasigma group.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Alfa Wassermann Proteomic Technologies.